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ABstrACt
Atrial fibrillation (AF) is the most prevalent form of alteration in cardiac rhythm and is associated with a high economic 
burden resulting from both clinical consequences and impact on patients’ quality of life. Goals of treatment include symp-
tom control and, in the high-risk patients, the prevention of thromboembolic complications. The advent of novel oral 
anticoagulant agents (NOACs) has improved the management of patients with non-valvular AF (NVAF) by overcoming 
limitations associated with traditional oral anticoagulation drugs. NOACs are associated with a lower risk of stroke, sys-
temic embolism, and mortality compared to vitamin K antagonists (VKAs) and with a lower risk of fatal, major, and intra-
cranial bleeding. This supplement aims at sharing the virtuous management model of AF patients in the Local Health Unit 
Tuscany North-West and promoting the importance of a multidisciplinary management, which involves cardiologists and 
general practitioners (GPs), not only in terms of clinical outcomes, but also of therapeutic appropriateness and economic 
sustainability.
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Introduction
Atrial fibrillation (AF) is the most prevalent form of alteration in cardiac rhythm and is 
associated with severe episodes of stroke, with a high degree of residual disability, and mor-
tality, particularly in patients ≥75 years.
The high economic burden of AF results from both clinical consequences (i.e. high num-
ber of cardiovascular events among which stroke is the most important one) and impact on 
patients’ quality of life [1]. It has been estimated that in European countries the total cost for 
the management of AF ranged from 0.28% to 2.6% of overall health expenditure [2-5] and the 
global prevalence and costs associated with AF are expected to increase in the next years due 
to progressive aging of the population and the increase in the prevalence of risk factors, such 
as obesity, hypertension, and diabetes mellitus [6,7]. An epidemiologic study estimated that in 
Europe in 2030 the prevalence of AF would be 2.7%-3.3% with about 280,000-340,000 new 
ischemic strokes, 3.5-6 million hospitalizations for AF, and 100-120 million outpatient visits 
[7]. In Italy, an observational study published in 2017 estimated a prevalence of AF equal to 
1.7% for a total of 1,036,448 cases [8].
Due to the high prevalence and the association with cardiovascular comorbidities (es-
pecially stroke), AF is considered a pathology characterized by a great economic and social 
burden [9]. It has been estimated that the mean cost for the acute management of stroke was 
about 20,000 €/year per patient plus 30,000 €/year per patient due to the management of the 
associated disability, which involved about 40% of stroke survivors, and indirect costs associ-
ated with loss of productivity [10-12]. Similar results came from a study conducted in UK, in 
which costs per patient over the first years after stroke arose from the costs of acute treatment 
(1-year vs 5-year healthcare costs were £ 13,452 and £ 17,963, respectively), while social care 
costs accounted for a greater proportion of the total care costs over time (£ 8,977 vs £ 28,076, 
respectively) [9].
Goals of treatment in the management of AF patients include the symptom control and, in 
the high-risk patients, the prevention of thromboembolic complications [13]. Particularly, as 
reported in the current European Guidelines [13], oral anticoagulation (OAC) is not indicated 
in the absence of clinical risk factors (CHA2DS2-VASc = 0), while it is highly recommended 
in subjects with AF and CHA2DS2-VASc ≥ 2 (if men) or ≥ 3 (if women) and should be con-
sidered in men with CHA2DS2-VASc = 1 and women with CHA2DS2-VASc = 2 [13].
Traditional OAC therapy with vitamin K antagonists (VKAs) demonstrated to reduce the 
risk of stroke by 64% vs placebo [14], but it is associated with some limitations, such as the 
need for regular dosage adjustment based on INR monitoring, the interaction with drugs and 
food, and the risk of major bleedings [15]. In the last years, the class of novel oral anticoagu-
lant agents (NOACs) has been introduced for the treatment of non-valvular AF (NVAF, which 
involves about 70% of all AF cases), resulting in an improvement in the prevention therapy of 
thromboembolic events in these patients. Indeed, NOACs are associated with a lower risk of 
stroke, systemic embolism, and mortality compared to VKAs [16]. Also, safety outcomes are 
improved with a lower risk of fatal, major, and intracranial bleeding [16].
As reported in the European Society of Cardiology (ESC) Guidelines [13], in patients with 
AF an integrated and multidisciplinary approach should be considered, in order to increase 
detection of AF, ensure adequate management and follow up, improve treatment adherence, 
and reduce hospitalizations and mortality. This supplement aims at sharing the virtuous man-
agement model of AF patients in the Local Health Unit Tuscany North-West and promoting 
the importance of a multidisciplinary management, which involves cardiologists and general 
practitioners (GPs), not only in terms of clinical outcomes, but also of therapeutic appropri-
ateness and economic sustainability.
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The Management of Atrial 
Fibrillation in the Local Health 
Unit Tuscany North-West
In the last seven years, several initiatives have been undertaken in the Local Health Unit 
Tuscany North-West to improve the management of patients with NVAF and reduce the rel-
evant adverse events and comorbidities.
Since 2012, a close collaboration has been established between cardiologists and GPs and 
this cooperation has allowed, not only to better manage the patients and improve communica-
tion between cardiologists and GPs, but also to collect and explore data about epidemiology, 
clinical practice, and populations state of health.
Furthermore, about five years ago the cardiology department of Versilia Hospital (Lido 
di Camariore, Lucca, Italy) decided to implement a new management pathway for patients 
with AF discharged from emergency room (ER), in order to reduce mortality, hospital, and 
ER admissions and improve the use of appropriate and innovative treatments such as oral 
anticoagulant drugs.
thE intEgrAtEd mAnAgEmEnt modEl
Over the years, several actions have been carried out in the Tuscany Region to increase the 
integration between hospital and GPs, such as grouping GPs (AFTs – Territorial Functional 
Aggregates), the Sanità d’iniziativa and, finally, the establishment of Case della Salute.
Sanità d’iniziativa is a model of care which involves GPs and specialists with the aim of 
early intercepting patients with chronic diseases (i.e. diabetes, heart failure, hypertension, 
diabetes, etc.) and preventing the condition’s exacerbation. Casa della salute is a place where 
citizens find social and health services charged to the Italian National Health Service. A mul-
tidisciplinary team works in the Case della Salute, which includes GPs, pediatricians, nurses, 
specialists, administrative figures, and social workers, and guarantees the patients’ overall 
management (medical records are shared), the continuity of care, and the integration between 
health and social assistance.
In 2012, the implementation of Sanità d’iniziativa allowed the beginning of the collabora-
tion between the Casa della Salute in Querceta (Lucca, Italy), which refers to AFT 6, and Dr 
Giancarlo Casolo, cardiologist at the Versilia Hospital. This integrated management model 
provides that, two mornings a month, Dr Casolo visits patients, referred by GPs, in the car-
diologic consulting room at Casa della Salute. Furthermore, he has access to the same source 
of information of GPs in terms of patients’ medical records, medical history, pharmaceutical 
prescriptions, and comorbidities.
Working together, in the same place, is a great opportunity for both specialists and GPs: 
cardiologists have the chance to leave the hospital context and to have a closer relationship 
with patients; furthermore the interaction with GPs is helpful to better understand the patient 
s’ characteristics and prescribe treatment and schedule follow-up accordingly. In the same 
way, from the GPs’ point of view, the presence of the cardiologist is a valuable diagnostic and 
therapeutic support that allows healthcare professionals, to share decisions, thus guaranteeing 
the best treatment to the patient and improving the use of available resources.
EpidEmiology of AtriAl fiBrillAtion in thE 
loCAl hEAlth unit tusCAny north-WEst
In the AFTs, GPs work with the same medical practice management software, which 
collects electronic health records in a common database. Using these data an observational 
study was carried out with the aim of investigating the prevalence of NVAF and the pharma-
coutilization of anticoagulant drugs in the Local Health Unit Tuscany North-West. The study, 
which analyzed health records of 42,545 patients from three out of six Tuscan AFTs, was 
presented at the ESC Congress 2016 [17].
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Results, which refer to 2015, showed the presence of NVAF in 1,260 patients, thus result-
ing in a prevalence of 2.95%, with percentages ranging from 2.5% (677 NVAF/26,797 total 
population) in AFTs 1+3, to 3.7% (583/15,748) in the AFT 6. Age and sex distribution of 
NVAF revealed a greater number of cases in the 80-85 (21.4%) and >85 (21%) age groups, 
while a similar prevalence was reported for males and females (52.4% vs 47.6%). Finally, 
the pharmacoutilizaton analysis highlighted that, overall, only 52% of patients with NVAF 
were treated with an oral anticoagulant drug (VKA and NOAC). A 2019 update of these data 
showed a greater number of patients (1,787 NVAF/44,000 total population), a consequent 
higher prevalence of NVAF (4.06%), and a higher percentage of patients treated with VKA 
and NOAC (61%).
This increase in the prevalence of NVAF are probably due to a greater awareness of atrial 
fibrillation through the implementation of regional health policies (i.e., Sanità d’iniziativa 
and Health goals), and initiatives of individual AFTs (i.e. screening during the flu vaccination 
campaign) and hospitals (i.e. the close collaboration between GPs and cardiologists).
thE mAnAgEmEnt of AtriAl fiBrillAtion 
in thE vErsiliA hospitAl
In the Versilia Hospital, patients who come to the ER with a first episode of NVAF, or with 
an increase in heart rate due to a pre-existing AF, or to a comorbid condition (i.e. pneumo-
nia), are visited by emergency room physicians, who manage pharmaceutical and electrical 
therapy, while cardiology consultation is only required in the most severe cases.
According to clinicians experience, it emerged that 1) there was a time gap between dis-
charge and start of anticoagulant therapy, and 2) most patients had a relapse a few days after 
discharge. For these reasons and with the aim to reduce adverse events due to the first episode 
of NVAF, a cardiologic consulting room for patients with AF discharged from ER was estab-
lished and a new management pathway has been implemented.
The new pathway provides that emergency room physicians act according to a proto-
col shared with cardiology, assess the type of AF (i.e. first episode or persistent), calculate 
CHADS-VASc score, and, if necessary, start anticoagulation therapy (i.e. low molecular 
weight heparin). Afterwards, patients refer to the cardiology consulting room and are called 
back to schedule a visit within 3-4 days.
During the visit, cardiologists perform an overall assessment of the patient, investig po-
tential causes of AF, perform an ECG, and calculate CHADS2-VASc and HAS BLED scores. 
If eligible for treatment with anticoagulant drugs, patients are sent to the GP with a treatment 
plan and a summary report.
A first assessment of this new management pathway showed that about half of patients 
accessing ER with an episode of AF are intercepted by the cardiology consulting room and 
a decrease in the readmissions to ER and non-programmed hospital admissions has been ob-
served. Furthermore, all patients with AF who were visited in the consulting room and were 
eligible for treatment, received prescription for anticoagulant therapy.
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The Burden of Atrial Fibrillation: 
A Review of Italian and 
International Literature
Aim
A review of the literature has been performed with the aim of estimating the clinical and 
economic impact of AF, the pharmacoutilization of NOACs, and the role of prescriptive ap-
propriateness on clinical and economic outcomes.
mEthods
The literature search was conducted using MEDLINE/PubMed and Google Scholar (time 
interval from 2015 to 2019) with no limitations on languages or geographical origin. The 
electronic search was supplemented by manual check of reference lists of included and not 
included studies. The keywords used for the search included: NVAF; AF; stroke; new oral 
anti-coagulant (NOAC); vitamin K antagonists (VKA); burden of illness; economic burden; 
RWD; registry; health care resource use; indirect and direct costs; compliance; adherence. 
Real world data and economic studies on costs, resources utilization, and pharmacoutilization 
in patients with AF have been included, while review and cost-effective analyses have been 
excluded.
rEsults
The literature search identified 58 studies; 
of these 39 were excluded and 19 met the in-
clusion criteria and were analyzed (Figure 1).
Overview of the main studies
Direct cost associated with AF
The EPICARDIA study [18] is an ob-
servational, prospective, and multicenter 
study which evaluated direct costs associ-
ated with patients with NVAF admitted to 
the emergency rooms of two Italian hospi-
tals between November 2004 and January 
2005. The study followed 86 patients (mean 
age 69.2 years; 50% males) with NVAF for 
a year after discharge from the ER and re-
corded the consumption of health resources 
(new emergency room visits, hospital admis-
sions, GPs or specialists visits, consumption 
of drugs, instrumental examinations). The 
results showed that the mean annual cost is 
about € 2,685 per patient, of which 83% is 
due to hospitalizations (Figure 2). 
Pharmacoutilization of 
anticoagulant therapy
The observational study of Ermini et 
al. [19] used data collected by databases of 
GPs of a Local Health Unit in Italy aiming 
at assessing prevalence of AF and pharma-
coutilization of OAC therapy. Between 2009 
and 2012, the study enrolled 1,413 with AF 
(prevalence = 2.09%) and highlighted the 
Figure 1. Flowchart of literature search
Figure 2. Distribution of costs per patient. Modified from [18]
1 Emergency room, day hospital, or hospital admission
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underuse of OAC therapy: only 39.56% of 
patients received oral anticoagulant, 30% 
received antiplatelet therapy, and 16.28% 
received prescriptions for both therapies 
(only 4.17% received them at the same time). 
Furthermore, about 14% of patients did not 
receive any prescription of antithrombotic 
drug.
The retrospective study of Cataldo et al. 
[20] aimed at comparing the discontinuation 
risk and health care resource consumption 
between VKAs and NOACs in newly treated 
patients with NVAF. Based on administrative 
databases of five Italian Local Healthcare 
Units, 2,909 patients treated with VKA and 
765 patients treated with NOAC with a dis-
charge diagnosis of NVAF between 2011 and 
2014 were included.
All patients included were followed from the first prescription date to the occurrence of 
any of the following events: a 90-day gap in therapy, switch to a different molecule or add-on 
of a different molecule into the regimen, death of patient, end of follow-up, all-cause hospi-
talizations, outpatient visits, and examinations.
Cox regression to model time to non-persistence within 12 months showed a 62% reduc-
tion in the risk of drug discontinuation in NOAC patients compared to VKA patients (HR: 
0.38 [0.33-0.44]). Furthermore, NOACs were associated with less mean total number of all-
cause hospitalizations, all-cause visits and examinations, compared to VKA (Table I).
GLORIA-AF is a prospective registry program describing antithrombotic treatment pat-
terns in patients with newly diagnosed NVAF at risk of stroke. It comprises three phases: 
phase 1, before the introduction of NOACs; phase 2, during the time of the introduction of 
dabigatran, the first NOAC; and phase 3, once NOACs have been established in clinical prac-
tice (still ongoing). Phase 1 involved 1,063 patients, of whom 32.8% received VKA, 41.7% 
acetylsalicylic acid, and 20.2% did not receive any antithrombotic therapy. The phase 2 aim 
was to describe the effectiveness and safety of dabigatran etexilate over 2 years from routine 
clinical practice in GLORIA-AF patients who are newly diagnosed with NVAF and at risk 
of stroke. In phase 2 (n = 15,092), the prescription of oral anticoagulant drugs has increased 
(79.9% of patients, of whom 47.6% received NOAC and 32.3% VKA) while 7.9% of patients 
remain undertreated. Europe-related data (Figure 3) confirm the improvement of anticoagula-
tion therapy (64.1% in phase 1 vs 89.8% in phase 2): particularly in phase 2, treatment with 
NOAC was more common than VKA (52.3% and 37.8%, respectively).
Treatment 
at Index date
Health care 
resources (n)
Health care resource utilization
Mean, n (SD) p
Outpatient visit
NOAC 955 1.84 (0.09) 0.0002
VKA 2,524 2.33 (0.09)
Laboratory examination
NOAC 4,796 9.24 (7.90) < 0.0001
VKA 26,347 24.35 (16.59)
Hospitalization
NOAC 189 0.36 (0.66) 0.0058
VKA 507 0.47 (0.80
Table I. Health care resource utilization on 12-month persistent users. Modified 
from [20]
Figure 3. Antithrombotic treatment patterns in Europe. Modified from [21]
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Pharmacoutilization and clinical and economic outcomes
Cowan et al. [22] estimated the correlation between stroke rates and OAC use in Eng-
land using data of patients with AF from 2006 to 2016. Results showed an increase in the 
prevalence of AF (from 1.29% to 1.71%) and in the hospitalization rate due to AF-related 
stroke/100,000 AF patients from 80/week in 2006 to 98/week in 2011. Afterwards, hospital 
episodes of AF-related stroke/100,000 AF patients decreased to 86/week in 2016. The use 
of anticoagulant drugs in patients at risk of stroke increased from 48.0% to 78.6% while the 
use of antiplatelet agents declined from 42.9% to 16.1%. Finally, after adjustment for AF 
prevalence, a 1% increase in the anticoagulant use was associated with a 0.8% decrease in the 
weekly rate of AF-related stroke.
The study of Maggioni et al. [23] aimed at assessing rates of hospitalization for AF, isch-
emic strokes, and major hemorrhages and prescriptions for VKAs, NOACs, and antiplatelet 
agents. Furthermore, yearly cost per patient with AF has been assessed. The study used the 
longitudinal “Ricerca e salute” database, which involves over 12 million inhabitants, and fol-
lowed 194,030 patients who was discharged alive with primary or secondary diagnosis of AF 
between January 2012 and December 2013 for one year. The results showed an increase in 
Figure 4. Yearly trends in antithrombotic drug use and in admissions for strokes and bleeds. Modified from [23]
Figure 5. Integrated yearly costs per AF patients from 2012 to 2015. Modified from [23]
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admissions for AF from 2012 (3.98 per 1,000 
subjects) to 2015 (4.35 per 1,000 subjects), 
an increase in the use of OACs (from 56.7% 
to 64.4%), largely due to NOACs uptake 
(from 0.8% to 27.7%), and a decrease in the 
prescriptions of antiplatelet agents. Figure 4, 
which reports the yearly trends in the anti-
thrombotic drug use and in the admissions 
for ischemic or hemorrhagic stroke and ma-
jor bleedings, shows a reduction in the rate of 
admissions for ischemic stroke, concomitant 
to the increased uptake of NOACs, while the 
rate of admissions for hemorrhagic stroke or 
major bleedings did not change substantially. 
Yearly cost per patient has decreased from 
2012 to 2015 thanks to reduced costs for hos-
pitalizations that offset the increase in drug 
costs (Figure 5).
Finally, a costing report published by 
NICE [24] aimed at assessing the economic 
impact of implementing the NICE guideline on atrial fibrillation in UK. In particular, the 
report focused on the recommendations that are deemed to have the greatest impact, such as:
 - Do not offer aspirin monotherapy solely for stroke prevention to people with AF.
 - Use the CHA2DS2-VASc stroke risk score to assess stroke risk in people with symptomatic 
or asymptomatic paroxysmal, persistent or permanent AF; atrial flutter; a continuing risk 
of arrhythmia recurrence after cardioversion back to sinus rhythm.
 - Refer people promptly at any stage if treatment fails to control the symptoms of AFR and 
referral for more specialized management is needed.
The report estimated that the effect of not offering aspirin to reduce stroke risk and assess-
ing stroke risk using CHA2DS2-VASc may result in an increase in the pharmaceutical costs 
which, however, would be compensated by the reduction of strokes (Table II).
Current treatment Future treatment
Drugs
Warfarin 34.32 46.76
Aspirin 22.49 2.50
Dabigatran etexilate 4.73 11.65
Rivaroxaban 4.73 11.65
Apixaban 4.73 11.65
No treatment 28.99 15.79
Estimated strokes  
(n x 100,000)
59 41
Costs (£ x 100,000)
Drugs 347 654
Adverse events 733 513
Total 1,080 1,168
Table II. Overview of clinical and economic impact of implementing guidelines 
recommendations
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Conclusions
The advent of NOACs has improved the management of patients with NVAF by overcom-
ing the limitations associated with traditional OAC drugs. Safety, efficacy, and effectiveness 
of NOACs have been confirmed by meta-analyses of randomized trials [16,25-29] and real-
world studies [30-33]. In addition to the effects on clinical outcomes (decreased risk of stroke, 
bleedings, and death compared to warfarin), NOACs are associated with rapid onset of action, 
fixed dosing, no need for INR monitoring, and fewer food and drug interactions.
The literature review reported in this supplement confirms the statistical correlation be-
tween the increase in the use of NOACs and the reduction of correlated adverse events and 
highlights the economic impact of these drugs on the total cost for the management of AF. 
NOACs are indeed more expensive than traditional OAC therapy, but the increase in the drug 
cost is compensated by the decrease in other cost items, such as hospitalizations and manage-
ment of the consequences of stroke. Therefore, it can be concluded that a greater therapeu-
tic appropriateness, in terms of increase in the use of NOACs, as recommended by clinical 
guidelines [13], would be associated with better clinical outcomes without increasing total 
management costs. Unfortunately, despite the clinical and economic advantages associated 
with NOACs, in Italy their use is still low, even in patients at high risk of stroke for which 
NOACs would be the most appropriate treatments.
Born with the aim of improving the management of patients with AF, the integrated model 
of care implemented in the Local Health Unit Tuscany North-West and described in this sup-
plement has been associated with several advantages. First, the analysis of data collected by 
the medical practice management software showed an improvement in the number of cases 
diagnosed and in the percentage of patients treated with NOAC from 2014-2015 to 2019. 
Already in 2015 (and again in 2019), the prevalence of NVAF was higher than the national 
mean, thus reflecting a major awareness of AF in this context. Since AF is often asymptom-
atic, GPs, as the points of first contact with the healthcare system, have indeed a crucial role 
in the early detection of the disease and, in this sense, Local Health Unit Tuscany North-West, 
thanks to the implementation of regional health policies, initiatives of individual AFTs, and 
hospitals, has always been a virtuous example in the diagnosis and management of AF.
Furthermore, the close collaboration which has been established between cardiologist and 
GPs at Casa della Salute, which includes the sharing of patients’ medical records, has allowed 
expanding and sharing skills, education, and experiences to provide patients with early diag-
nosis and the best management. This integrated approach is reflected not only in better clinical 
outcomes, but also in greater appropriateness and economic sustainability.
Importance of integrated management of patients with AF is also acknowledged by ESC 
Guidelines, which suggest to involve non-specialists professionals in educating patients, co-
ordinating care and, where appropriate, starting the treatment and improving adherence. A 
prompt access to specialist knowledge is also required to optimize care and, in all patients 
with newly diagnosed AF, to help overcome the current limitations of AF management, such 
as underuse of OAC therapy, improve cardiovascular risk reduction, and fully evaluate the ef-
fect of AF on cardiovascular health [13]. Furthermore, as reported by Perino et al. [34], when 
patients with newly diagnosed AF receive cardiology care, instead of primary care only, clini-
cal outcomes in terms of strokes and death are improved, probably due to early prescription 
of OAC therapy.
Unfortunately, this virtuous model of integration is not applied in other AFTs due to the 
lack of cardiologists, absence of Casa della Salute, and political and economic decisions. In 
the future, it would be desirable to extend in every AFT the integration with the cardiologist 
(with the sharing of medical records), the training of GPs in the management of AF, and the 
extension of professionals authorized to prescribe NOACs or, at least, to renew the treatment 
plan. Also, indicators should be identified in order to evaluate efficacy and effectiveness of the 
integrated management model.
14 Farmeconomia. Health economics and therapeutic pathways 2019; 20(Suppl 1)
Conclusions
Finally, it should be interesting to assess if this new model of care is associated with an 
appropriate therapeutic taking care of AF patients which allows avoiding adverse events oc-
currence and a sustainable model according to Local Health Unit Tuscany North-West per-
spective in terms of reduction in resource utilization and disability.
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